MELVILLE, N.Y., Nov. 11, 2016 /PRNewswire/ -- Studying or working with rare alleles is problematic because there are often a limited number of samples for the target. Often, researchers must collect approximately twenty samples to genotype using cluster analysis, a common genotyping technique. Canon BioMedical's Novallele genotyping assays based on high-resolution melting (HRM) analysis can quickly genotype a single sample without requiring a large group of samples; however, the ideal genotyping method includes known controls to ensure confidence in the final results. Biobanks and other sample repositories often do not have reference samples of these low-frequency alleles that are associated with rare diseases. In addition to our HRM assays, we are thrilled to help researchers solve this problem by providing a set of controls as a companion to their Novallele genotyping assay. The Novallele Control Set gives researchers confidence in their genotyping call for even just a single sample.
The controls are run as a sample in the corresponding Novallele genotyping assay, and scientists can genotype their samples by comparing the sample melt curves to the Novallele Control Set melt curves. Each Novallele Control Set contains two controls, a homozygous wild-type (WT) and a homozygous mutant (HOM). An optional heterozygous (HET) control is prepared by combining the WT and HOM controls, providing all three genotypes for a specific target.
"We constantly engage with genetic researchers working to understand their work. By listening to our customers, we try to create solutions that address their problems," states Dennis Snyder, Senior Director of Global Commercial Operations for Canon BioMedical. "Everyone wants a reliable control for their experiment, and now we can provide that product to our customers — giving them confidence in their result, even when they run just a single sample."
Complete details about each Novallele Control Set are now available at www.canon-biomedical.com. In addition, Canon BioMedical will present the Novallele Control Set at the Association for Molecular Pathology 2016 Annual Meeting in Charlotte, North Carolina. Find us at booth 602 in the Exhibit Hall to talk about how our Novallele genotyping assays and controls can help you genotype your toughest targets with technology already in your laboratory.
About Canon BioMedical
Canon BioMedical, a wholly owned subsidiary of Canon U.S.A., Inc., is focused on empowering the biomedical research and healthcare communities by developing, manufacturing, and marketing innovative technologies and solutions. The technologies and solutions developed will help enable clinicians and scientists to improve our health and advance science. Canon BioMedical will continue to pursue innovative solutions in line with Canon's Kyosei philosophy of social and environmental responsibility through the use of existing and emerging Canon technology as well as strategic partnerships.
Products mentioned in this release are for Research Use Only. Not for use in diagnostic procedures.
All referenced product names, and other marks, are trademarks of their respective owners.
© 2016 Canon BioMedical, Inc. All rights reserved.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/canon-biomedical-launches-the-novallele-control-set-300361611.html
SOURCE Canon U.S.A., Inc.